Alembic Pharmaceuticals Limited has released its investor presentation for the quarter and nine months ended December 31, 2025 (Q3 FY26). The company reported a total revenue of ₹18.76 billion for the quarter, an 11% year-on-year increase. The Ex-US Generics business was a significant contributor, achieving a 36% year-on-year growth and reaching an all-time high in revenue. The India Branded business saw a 6% year-on-year growth with quarterly revenues of ₹6.52 billion. The US Generics business also reported a 6% year-on-year increase, driven by new product launches and market share gains. The API business maintained stable growth with a 2% increase in revenue. Key financial highlights for Q3 FY26 include EBITDA of ₹3.08 billion and Net Profit Before Tax (Before Exceptional Items) of ₹2.04 billion, representing a 33% year-on-year increase. R&D expenditure was 9% of revenue. The company continues to invest in building its product pipelines, with a focus on complex platforms and specialty divisions in the US. Alembic Pharmaceuticals also highlighted its sustainability targets, including Net Zero by 2050 and Water Neutrality by 2027.
